Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin
- PMID: 8556484
- PMCID: PMC368287
- DOI: 10.1128/cdli.1.4.450-463.1994
Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin
Abstract
Several immunodeficient rodent models currently exist in which persistent, largely asymptomatic, Cryptosporidium parvum infections can be established. Piglets, in contrast, develop a self-limiting diarrheal illness. We have consequently developed an animal model system in which scid mice were used to screen drugs for inhibitory activity against C. parvum, after which the drugs' therapeutic potential was evaluated with piglets. Paromomycin and hyperimmune bovine colostrum-immunoglobulin were selected to evaluate this system. C. paravum infections in suckling scid mice tended to be associated with villus surfaces, while in weaned and in older scid mice infections were more commonly localized in abscessed crypts. Rates of oocyst shedding in suckling scid mice were 50 to 200 times higher than in weaned mice and therefore made suckling mice a considerably more sensitive model for drug testing. Paromomycin given in high doses over 9 to 10 days was not toxic to either scid mice (3,000 mg/kg of body weight per day) or piglets (500 mg/kg/day). Paromomycin treatment was very effective against villus surface infections in suckling mice and considerably less effective against infections in inaccessible sites such as abscessed crypts and stomach pits seen in weaned and adult scid mice. The therapeutic efficacy of paromomycin in piglets depended on the severity of the diarrheal illness. Mild to moderate diarrhea and infection were cleared after paromomycin treatment of piglets infected with one C. parvum isolate. However, paromomycin had no impact on severely affected piglets infected with a second isolate, presumably because of a rapid transit time through the gut. In contrast to paromomycin hyperimmune bovine colostrum-immunoglobulin treatment reduced the rate of C. parvum infection moderately in scid mice and only slightly in piglets, again probably because of a rapid transit time through the gut and inactivation in the stomach. It was also clear that the impact of effective drugs against C. parvum can be detected within 5 days after the onset of treatment in either model.
Similar articles
-
Treatment of experimental ovine cryptosporidiosis with ovine or bovine hyperimmune colostrum.Vet Parasitol. 1994 Jun;53(3-4):173-90. doi: 10.1016/0304-4017(94)90181-3. Vet Parasitol. 1994. PMID: 7975113
-
Bovine antibody against Cryptosporidium parvum elicits a circumsporozoite precipitate-like reaction and has immunotherapeutic effect against persistent cryptosporidiosis in SCID mice.Infect Immun. 1994 May;62(5):1927-39. doi: 10.1128/iai.62.5.1927-1939.1994. Infect Immun. 1994. PMID: 8168959 Free PMC article.
-
Comparative efficacy of curcumin and paromomycin against Cryptosporidium parvum infection in a BALB/c model.Vet Parasitol. 2018 Jan 30;250:7-14. doi: 10.1016/j.vetpar.2017.12.008. Epub 2017 Dec 9. Vet Parasitol. 2018. PMID: 29329627
-
Treatment of cryptosporidial diarrhea in an AIDS patient with paromomycin.Ann Pharmacother. 1993 Dec;27(12):1460-2. doi: 10.1177/106002809302701209. Ann Pharmacother. 1993. PMID: 8305777 Review.
-
[Advances in researches on anti-Cryptosporidium parvum hyperimmune bovine colostrum].Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1999;17(2):119-22. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1999. PMID: 12563798 Review. Chinese. No abstract available.
Cited by
-
Therapeutic Efficacy of Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium hominis.Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00147-18. doi: 10.1128/AAC.00147-18. Print 2018 Jul. Antimicrob Agents Chemother. 2018. PMID: 29661877 Free PMC article.
-
Sequence polymorphism in the beta-tubulin gene reveals heterogeneous and variable population structures in Cryptosporidium parvum.Appl Environ Microbiol. 1998 Nov;64(11):4477-81. doi: 10.1128/AEM.64.11.4477-4481.1998. Appl Environ Microbiol. 1998. PMID: 9797309 Free PMC article.
-
Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis.Antimicrob Agents Chemother. 2014;58(3):1603-14. doi: 10.1128/AAC.02075-13. Epub 2013 Dec 23. Antimicrob Agents Chemother. 2014. PMID: 24366728 Free PMC article.
-
A new restriction fragment length polymorphism from Cryptosporidium parvum identifies genetically heterogeneous parasite populations and genotypic changes following transmission from bovine to human hosts.Infect Immun. 1997 Sep;65(9):3958-60. doi: 10.1128/iai.65.9.3958-3960.1997. Infect Immun. 1997. PMID: 9284180 Free PMC article.
-
Mediation of Cryptosporidium parvum infection in vitro by mucin-like glycoproteins defined by a neutralizing monoclonal antibody.Infect Immun. 2000 Sep;68(9):5167-75. doi: 10.1128/IAI.68.9.5167-5175.2000. Infect Immun. 2000. PMID: 10948140 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical